MMRGlobal Announces First Quarter 2013 Filing, Expansion of Health IT Patent Licensing Efforts Abroad, While CEO Introduces

MMRGlobal Announces First Quarter 2013 Filing, Expansion of Health IT Patent 
Licensing Efforts Abroad, While CEO Introduces Company on Fox
News Radio 
LOS ANGELES, CA -- (Marketwired) -- 05/15/13 --  MMRGlobal, Inc.
(OTCQB: MMRF) ("MMR"), a leading provider of Personal Health Records
(PHRs), MyEsafeDepositBox storage solutions and electronic document
management and imaging systems for healthcare professionals, today
announced that the Company's primary business will be expanded from
its previous focus of selling consumer and professional products and
services, including its MyMedicalRecords PHR and MMRPro document
imaging and scanning systems, to equally exploiting and licensing its
health information technology patents domestically and
internationally. The Company markets MyMedicalRecords and MMRPro
throughout the United States and other countries and territories
where it has licensees and strategic partners such as in Australia,
Japan and China. The Company is also retaining counsel in Australia
and Singapore in support of efforts to protect its patents and other
intellectual property in those countries. Additionally, the Company
announced that the European Commission has recently granted orphan
designation for Lenalidomide as an orphan medicinal product for the
treatment of follicular lymphoma. This drug is the subject of the
MMR's non-exclusive biotech license agreement
and the Company sees this announcement as a positive step toward the
achievement of remaining milestone payments due under the biotech
licensing agreement. MMR is also planning on continuing its efforts
to license its biotechnology patents, patient samples and related IP. 
MMRGlobal CEO Robert H. Lorsch is scheduled to appear on Fox News
Radio's "The Vipp Jaswal Report" this Thursday at 11:00 a.m. PDT /
2:00 p.m. EDT, where he will discuss MMR and his efforts on behalf of
a campaign to encourage Congress to direct portions of a $27 billion
stimulus budget to emerging growth companies who provision
interoperable patient-facing Personal Health Records for their
eligible healthcare customers. The Vipp Jaswal Report is broadcast
all across America and internationally on Fox News Radio. After
Lorsch's scheduled appearance on the May 16th show, the 30-minute
interview will be available on the Internet at the Company's Facebook
page following the broadcast
MMR provides patented Personal Health Record products and services to
consumers, employers, associations, hospitals and healthcare
professionals, and retailers and other strategic partners. Customers
and licensees include Regent Surgical Health, Alcatel-Lucent, ng
Connect, 4medica, Interbit Data, Vida Senior Resource and affiliated
home healthcare agencies, VisiInc in Australia and Unis-Tonghe
Technology (Zhengzhou) Co., Ltd. in China, as well as independent
pharmacies, pharmacy chains and other retailers and mass
merchandisers nationwide, visiting nurses, caregivers, patient
advocates, medical supply companies and in-home sales affiliates.  
The Company also announced that it has filed its quarterly report on
Form 10-Q for the period ended March 31, 2013 with the United States
Securities and Exchange Commission. The Company reported a reduction
in net losses of 4.6% from $1,584,201 for the first quarter of 2012
to $1,511,821 for the same period in 2013. $342,731 of this were
non-cash losses attributable to expenditures which stem mainly from
the application of accounting principles including but not limited to
stock options, warrants and common stock issued for services, among
other similar types of expenses.  
The Company projects sales to increase in future quarters from HIT
license agreements and MMRPro sales from the existing VisiInc
contracts. Shipment of approximately $600,000 in VISI MMRPro systems
had been delayed due to additional integration requirements requested
by Burkhart Dental and Synnex specifically to back-up data from an
MMRPro system to a Seagate NAS box. Requirements also included
building seamless integration of MMRPro with Dentrix, the software
used by the dentists in the Burkhart channel. The Company also
expects to receive additional biotech milestone payments of up to
$12.65 million, pursuant to one existing non-exclusive license
agreement. To date, the Company has already received $850,000 in
biotech milestone payments. 
Costs of Revenue decreased by $148,706, or 85%, from $174,849 in the
first quarter of 2012 to $26,143 in 2013. General and Administrative
expenses declined by $44,204, or 4.7%, from $933,766 in the first
quarter of 2012 to $889,562 in 2013. Sales and marketing expenses
increased by $106,379, or 23.5%, from $452,644 in the first quarter
of 2012 to $559,023 in 2013 due to higher marketing and consulting
fees as part of the Company's efforts to generate HIT licensing
revenues from the exploitation of HIT patents and increased sales of
MMRPro and PHRs. Technology and product development expenses
decreased by $46,004, or 65.7%, from $69,977 in the first quarter of
2012 to $23,973 in 2013 as a result of improved efficiencies in
dealing with our overseas resources.  
MMR has seven issued U.S. patents as well as additional applications
and continuation applications with nearly 400 claims relating to
Personal Health Records transmitted via an Internet portal under the
heading of "Method and System for Providing Online Medical Records"
and "Method and System for Providing Online Records." MMR's patent
portfolio also includes numerous other issued patents and pending
applications in countries of commercial interest around the world
which include Australia, Singapore, New Zealand, Mexico, Canada,
Japan, Hong Kong, South Korea, Israel, and European nations.  
The Company also continues efforts to maximize the current and future
value of its biotech intellectual property that was acquired through
its reverse merger with Favrille, Inc. in January 2009. These biotech
assets include the exploitation and licensing of patents, data and
over 1,800 patient samples from the Company's pre-merger clinical
vaccine trials, the FavId(TM)/Specifid(TM) vaccine, and exploiting
the anti-CD20 antibodies to treat B-cell lymphomas.  
About MMRGlobal, Inc. 
 MMRGlobal, Inc., through its wholly-owned
operating subsidiary, MyMedicalRecords, Inc., provides secure and
easy-to-use online Personal Health Records ("PHRs") and electronic
safe deposit box storage solutions, serving consumers, healthcare
professionals, employers, insurance companies, financial
institutions, and professional organizations and affinity groups. The
MyMedicalRecords PHR enables individuals and families to access their
medical records and other important documents, such as birth
certificates, passports, insurance policies and wills, anytime from
anywhere using the Internet. MyMedicalRecords is built on
proprietary, patented technologies to allow documents, images and
voicemail messages to be transmitted and stored in the system using a
variety of methods, including fax, phone, or file upload without
relying on any specific electronic medical record platform to
populate a user's account. The Company's professional offering,
MMRPro, is designed to give physicians' offices an easy and
cost-effective solution to digitizing paper-based medical records and
sharing them with patients in real time through an integrated patient
portal. MMR is an Independent Software Vendor Partner with Kodak to
deliver an integrated turnkey EMR solution for healthcare
professionals. Through its merger with Favrille, Inc. in January
2009, the Company acquired intellectual property biotech assets that
include anti-CD20 antibodies and data and samples from its
FavId(TM)/Specifid(TM) vaccine clinical trials for the treatment of
B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc.
visit View demos and video tutorials of the
Company's products and services at 
Forward-Looking Statements 
 All statements in this press release
that are not strictly historical in nature, including but not limited
to future performance, management's expectations, beliefs,
intentions, estimates or projections, constitute "forward-looking
statements." Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the
Company's actual results to be materially different from historical
results or from any results expressed or implied by such
forward-looking statements. Some can be identified by the use of
words (and their derivations) such as "need," "possibility,"
"potential," "intend," "offer," "development," "if," "negotiate,"
"when," "begun," "believe," "achieve," "will," "estimate," "expect,"
"maintain," "plan," and "continue," or the negative of these words.
Actual outcomes and results of operations and the timing of selected
events may differ materially from the results predicted, and any
reported results should not be considered as an indication of future
performance. Such statements are necessarily based on assumptions and
estimates and are subject to various risks and uncertainties,
including those relating to the possible invalidity of the underlying
assumptions and estimates and possible changes or developments in
economic, business, industry, market, legal and regulatory
circumstances and conditions and actions taken or omitted to be taken
by third parties, including customers, suppliers, business partners,
potential licensees, competitors and legislative, judicial and other
governmental authorities and officials. Factors that could cause or
contribute to such differences include, but are not limited to:
unexpected outcomes with respect to intellectual property enforcement
actions, claims of intellectual property infringement and general
intellectual property litigation; our ability to maintain, develop,
monetize and protect our patent portfolio for both the Company's
health IT and biotechnology intellectual property assets in the U.S.
and internationally; the timing of milestone payments in connection
with licensing our intellectual property; our ability to establish
and maintain strategic relationships; changes in our relationships
with our licensees; the risk the Company's products are not adopted
or viewed favorably by the healthcare community and consumer retail
market; business prospects, results of operations or financial
condition, including variations in our quarterly operating results;
risks related to the current uncertainty and instability in financial
and lending markets, including global economic uncertainties; the
timing and volume of sales and installations; the length of sales
cycles and the installation process; the market's acceptance of new
product and service introductions; competitive product offerings and
promotions; changes in government laws and regulations including the
2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable
Care Act; future changes in tax legislation and initiatives in the
healthcare industry; undetected errors in our products; the
possibility of interruption at our data centers; risks related to
third party vendors; risks related to obtaining and integrating
third-party licensed technology; risks related to a security breach
by third parties; risks associated with recruitment and retention of
key personnel; other litigation matters; uncertainties associated
with doing business internationally across borders and territories;
and additional risks discussed in the Company's filings with the
Securities and Exchange Commission. The Form 10-Q is available on the
MMRGlobal Web site in the Investor Relations section. The Company is
providing this information as of the date of this release and, except
as required by applicable law, does not undertake any obligation to
update any forward-looking statements contained in this release as a
result of new information, future events or otherwise.   
Michael Selsman
Public Communications Co.
(310) 922-7033 
Press spacebar to pause and continue. Press esc to stop.